Cannabidiol, neuroprotection and neuropsychiatric disorders

Pharmacological Research

Volumn 112, Issue , 2016, Pages 119-127

  Campos, Alline C ^a   Fogaça, Manoela V ^a   Sonego, Andreza B ^a   Guimarães, Francisco S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

5HT1A receptor; Cannabidiol; Endocannabinoids; Neuropsychiatric disorders; Oxidative stress; PPAR receptor

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; ALPHA TOCOPHEROL; ANTIDEPRESSANT AGENT; ASCORBIC ACID; CANNABIDIOL; CANNABINOID; CANNABIS; DRONABINOL; NABIXIMOLS; NEUROPROTECTIVE AGENT;

ANXIETY; BRAIN DAMAGE; BRAIN FUNCTION; BRAIN ISCHEMIA; DEGENERATIVE DISEASE; DEPRESSION; DRUG EFFECT; DRUG TARGETING; EPILEPSY; HUMAN; MENTAL DISEASE; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SPASTICITY; ANIMAL; BRAIN DISEASES; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; MENTAL DISORDERS;

ANIMALS; BRAIN DISEASES; CANNABIDIOL; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; MENTAL DISORDERS; NEUROPROTECTION; NEUROPROTECTIVE AGENTS;

EID: 84989157861     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.01.033     Document Type: Review

References (119)

1. [1] World Health Organization. WHO methods and data sources for global burden of disease estimates 2000–2011. Department of Health Statistics and Information Systems WHO, Geneva (2013).
2. [2] Roy, M., Tapadia, M.G., Joshi, S., Koch, B., Molecular and genetic basis of depression. J. Genet. 93 (2014), 879–892.
3. [3] Lopizzo, N., Bocchio Chiavetto, L., Cattane, N., Plazzotta, G., Tarazi, F.I., Pariante, C.M., Riva, M.A., Cattaneo, A., Gene-environment interaction in major depression: focus on experience-dependent biological systems. Front. Psychiatry, 6, 2015, 68.
4. [4] Levinstein, M.R., Samuels, B.A., Mechanisms underlying the antidepressant response and treatment resistance. Front. Behav. Neurosci., 8(208), 2014.
5. [5] Kalivasand O'Brien, P.W.C., Drug addiction as a pathology of staged neuroplasticity. Neuropsychopharmacology 33 (2008), 166–180.
6. [6] Castren, E., Neuronal network plasticity and recovery from depression. JAMA Psychiatry 70 (2013), 983–989.
7. [7] Bredt, D.S., Furey, M.L., Chen, G., Lovenberg, T., Drevets, W.C., Manji, H.K., Translating depression biomarkers for improved targeted therapies. Neurosci. Biobehav. Rev. 59 (2015), 1–15.
8. [8] Shah, A., Carreno, F.R., Frazer, A., Therapeutic modalities for treatment resistant depression: focus on vagal nerve stimulation and ketamine. Clin. Psychopharmacol. Neurosci. 12 (2014), 83–93.
9. [9] Zhang, K., Jiang, H., Zhang, Q., Du, J., Wang, Y., Zhao, M., Brain-derived neurotrophic factor serum levels in heroin-dependent patients after 26weeks of withdrawal. Compr. Psychiatry 65 (2016), 150–155.
10. [10] Wee, N., Kandiah, N., Acharyya, S., Chander, R.J., Ng, A., Au, W.L., Tan, L.C., Depression and anxiety are co-morbid but dissociable in mild Parkinson's disease: A prospective longitudinal study of patterns and predictors. Parkinsonism Relat. Disord., 2016, 10.1016/j.parkreldis.2015.12.001 in press.
11. [11] Sheline, Y.I., West, T., Yarasheski, K., Swarm, R., Jasielec, M.S., Fisher, J.R., Ficker, W.D., Yan, P., Xiong, C., Frederiksen, C., Grzelak, M.V., Chott, R., Bateman, R.J., Morris, J.C., Mintun, M.A., Lee, J.M., Cirrito, J.R., An antidepressant decreases CSF Abeta production in healthy individuals and in transgenic AD mice. Sci. Transl. Med., 6, 2014 236re234.
12. [12] Ng, K.L., Gibson, E.M., Hubbard, R., Yang, J., Caffo, B., O'Brien, R.J., Krakauer, J.W., Zeiler, S.R., Fluoxetine maintains a state of heightened responsiveness to motor training early after stroke in a mouse model. Stroke 46 (2015), 2951–2960.
13. [13] Nestler, E.J., Barrot, M., DiLeone, R.J., Eisch, A.J., Gold, S.J., Monteggia, L.M., Neurobiology of depression. Neuron 34 (2002), 13–25.
14. [14] Xue, X., Shao, S., Wang, W., Shao, F., Maternal separation induces alterations in reversal learning and brain-derived neurotrophic factor expression in adult rats. Neuropsychobiology 68 (2013), 243–249.
15. [15] Liu, D., Wang, Z., Liu, S., Wang, F., Zhao, S., Hao, A., Anti-inflammatory effects of fluoxetine in lipopolysaccharide(LPS)-stimulated microglial cells. Neuropharmacology 61 (2011), 592–599.
16. [16] Ramirez, K., Shea, D.T., McKim, D.B., Reader, B.F., Sheridan, J.F., Imipramine attenuates neuroinflammatory signaling and reverses stress-induced social avoidance. Brain Behav. Immun. 46 (2015), 212–220.
17. [17] Campos, A.C., Moreira, F.A., Gomes, F.V., Del Bel, E.A., Guimaraes, F.S., Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos. Trans. R. Soc. Lond. B Biol. Sci. 367 (2012), 3364–3378.
18. [18] Fernandez-Ruiz, J., Sagredo, O., Pazos, M.R., Garcia, C., Pertwee, R., Mechoulam, R., Martinez-Orgado, J., Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?. Br. J. Clin. Pharmacol. 75 (2013), 323–333.
19. [19] Russo, E., Guy, G.W., A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med. Hypotheses. 66 (2006), 234–246.
20. [20] Mechoulam, R., Gaoni, Y., Hashish, I.V., The isolation and structure of cannabinolic cannabidiolic and cannabigerolic acids. Tetrahedron 21 (1965), 1223–1229.
21. [21] Pertwee, R.G., Pharmacological actions of cannabinoids. Handb. Exp. Pharmacol., 2005, 1–51.
22. [22] Zuardi, A.W., Cosme, R.A., Graeff, F.G., Guimaraes, F.S., Effects of ipsapirone and cannabidiol on human experimental anxiety. J. Psychopharmacol. 7 (1993), 82–88.
23. [23] Linge, R., Jimenez-Sanchez, L., Campa, L., Pilar-Cuellar, F., Vidal, R., Pazos, A., Adell, A., Diaz, A., Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT receptors. Neuropharmacology 103 (2015), 16–26.
24. [24] Campos, A.C., Brant, F., Miranda, A.S., Machado, F.S., Teixeira, A.L., Cannabidiol increases survival and promotes rescue of cognitive function in a murine model of cerebral malaria. Neuroscience 289 (2015), 166–180.
25. [25] Silveira, J.W., Issy, A.C., Castania, V.A., Salmon, C.E., Nogueira-Barbosa, M.H., Guimaraes, F.S., Defino, H.L., Del Bel, E., Protective effects of cannabidiol on lesion-induced intervertebral disc degeneration. PLoS One, 9, 2014, e113161.
26. [26] Schiavon, A.P., Soares, L.M., Bonato, J.M., Milani, H., Guimaraes, F.S., Weffort de Oliveira, R.M., Protective effects of cannabidiol against hippocampal cell death and cognitive impairment induced by bilateral common carotid artery occlusion in mice. Neurotoxic. Res. 26 (2014), 307–316.
27. [27] Perez, M., Benitez, S.U., Cartarozzi, L.P., Del Bel, E., Guimaraes, F.S., Oliveira, A.L., Neuroprotection and reduction of glial reaction by cannabidiol treatment after sciatic nerve transection in neonatal rats. Eur. J. Neurosci. 38 (2013), 3424–3434.
28. [28] Kwiatkoski, M., Guimaraes, F.S., Del-Bel, E., Cannabidiol-treated rats exhibited higher motor score after cryogenic spinal cord injury. Neurotoxic. Res. 21 (2012), 271–280.
29. [29] Esposito, G., Scuderi, C., Valenza, M., Togna, G.I., Latina, V., De Filippis, D., Cipriano, M., Carratu, M.R., Iuvone, T., Steardo, L., Cannabidiol reduces Abeta-induced neuroinflammation and promotes hippocampal neurogenesis through PPARgamma involvement. PLoS One, 6, 2011, e28668.
30. [30] Mecha, M., Feliu, A., Inigo, P.M., Mestre, L., Carrillo-Salinas, F.J., Guaza, C., Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors. Neurobiol. Dis. 59 (2013), 141–150.
31. [31] Napimoga, M.H., Benatti, B.B., Lima, F.O., Alves, P.M., Campos, A.C., Pena-Dos-Santos, D.R., Severino, F.P., Cunha, F.Q., Guimaraes, F.S., Cannabidiol decreases bone resorption by inhibiting RANK/RANKL expression and pro-inflammatory cytokines during experimental periodontitis in rats. Int. Immunopharmacol. 9 (2009), 216–222.
32. [32] Ben-Shabat, L.O., Katzavian, G., Gallily, R., New cannabidiol derivatives: synthesis, binding to cannabinoid receptor, and evaluation of their antiinflammatory activity. J. Med. Chem. 49 (2006), 1113–1117.
33. [33] Malfait, A.M., Gallily, R., Sumariwalla, P.F., Malik, A.S., Andreakos, E., Mechoulam, R., Feldmann, M., The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 9561–9566.
34. [34] Kozela, E., Pietr, M., Juknat, A., Rimmerman, N., Levy, R., Vogel, Z., Cannabinoids delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells. J. Biol. Chem. 285 (2010), 1616–1626.
35. [35] Kozela, E., Lev, N., Kaushansky, N., Eilam, R., Rimmerman, N., Levy, R., Ben-Nun, A., Juknat, A., Vogel, Z., Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice. Br. J. Pharmacol. 163 (2011), 1507–1519.
36. [36] Alvarez, F.J., Lafuente, H., Rey-Santano, M.C., Mielgo, V.E., Gastiasoro, E., Rueda, M., Pertwee, R.G., Castillo, A.I., Romero, J., Martinez-Orgado, J., Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets. Pediatr. Res. 64 (2008), 653–658.
37. [37] Ruiz-Valdepenas, L., Martinez-Orgado, J.A., Benito, C., Millan, A., Tolon, R.M., Romero, J., Cannabidiol reduces lipopolysaccharide-induced vascular changes and inflammation in the mouse brain: an intravital microscopy study. J. Neuroinflammation, 8, 2011, 5.
38. [38] Mishima, K., Hayakawa, K., Abe, K., Ikeda, T., Egashira, N., Iwasaki, K., Fujiwara, M., Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism. Stroke 36 (2005), 1077–1082.
39. [39] https.//clinicaltrials.gov (accessed 01.16.).
40. [40] Bergamaschi, M.M., Queiroz, R.H., Zuardi, A.W., Crippa, J.A., Safety and side effects of cannabidiol: a Cannabis sativa constituent. Curr. Drug Saf. 6 (2011), 237–249.
41. [41] Scuderi, C., Filippis, D.D., Iuvone, T., Blasio, A., Steardo, A., Esposito, G., Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. Phytother. Res. 23 (2009), 597–602.
42. [42] Szabo, B., Schlicker, E., Effects of cannabinoids on neurotransmission. Handb. Exp. Pharmacol., 2005, 327–365.
43. [43] Kreitzer, A.C., Neurotransmission: emerging roles of endocannabinoids. Curr. Biol. 15 (2005), R549–R551.
44. [44] Garcia-Arencibia, M., Gonzalez, S., de Lago, E., Ramos, J.A., Mechoulam, R., Fernandez-Ruiz, J., Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res. 1134 (2007), 162–170.
45. [45] Melis, M.R., Succu, S., Mascia, M.S., Sanna, F., Melis, T., Castelli, M.P., Argiolas, A., The cannabinoid receptor antagonist SR-141716A induces penile erection in male rats: involvement of paraventricular glutamic acid and nitric oxide. Neuropharmacology 50 (2006), 219–228.
46. [46] Kreutz, S., Koch, M., Bottger, C., Ghadban, C., Korf, H.W., Dehghani, F., 2-Arachidonoylglycerol elicits neuroprotective effects on excitotoxically lesioned dentate gyrus granule cells via abnormal-cannabidiol-sensitive receptors on microglial cells. Glia 57 (2009), 286–294.
47. [47] Thomas, A., Ross, R.A., Saha, B., Mahadevan, A., Razdan, R.K., Pertwee, R.G., 6-Azidohex-2-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist. Eur. J. Pharmacol. 487 (2004), 213–221.
48. [48] Thomas, A., Baillie, G.L., Phillips, A.M., Razdan, R.K., Ross, R.A., Pertwee, R.G., Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br. J. Pharmaco. 150 (2007), 613–623.
49. [49] Bisogno, T., Hanus, L., De Petrocellis, L., Tchilibon, S., Ponde, D.E., Brandi, I., Moriello, A.S., Davis, J.B., Mechoulam, R., Di Marzo, V., Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol. 134 (2001), 845–852.
50. [50] Pertwee, R.G., The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br. J. Pharmacol. 153 (2008), 199–215.
51. [51] Castillo, A., Tolon, M.R., Fernandez-Ruiz, J., Romero, J., Martinez-Orgado, J., The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB(2) and adenosine receptors. Neurobiol. Dis. 37 (2010), 434–440.
52. [52] Campos, A.C., Ortega, Z., Palazuelos, J., Fogaca, M.V., Aguiar, D.C., Diaz-Alonso, J., Ortega-Gutierrez, S., Vazquez-Villa, H., Moreira, F.A., Guzman, M., Galve-Roperh, I., Guimaraes, F.S., The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system. Int. J. Neuropsychopharmacol. 16 (2013), 1407–1419.
53. [53] Stern, C.A., Gazarini, L., Takahashi, R.N., Guimaraes, F.S., Bertoglio, L.J., On disruption of fear memory by reconsolidation blockade: evidence from cannabidiol treatment. Neuropsychopharmacology 37 (2012), 2132–2142.
54. [54] Casarotto, P.C., Gomes, F.V., Resstel, L.B., Guimaraes, F.S., Cannabidiol inhibitory effect on marble-burying behaviour: involvement of CB1 receptors. Behav. Pharmacol. 21 (2010), 353–358.
55. [55] Pazos, M.R., Mohammed, N., Lafuente, H., Santos, M., Martinez-Pinilla, E., Moreno, E., Valdizan, E., Romero, J., Pazos, A., Franco, R., Hillard, C.J., Alvarez, F.J., Martinez-Orgado, J., Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: role of 5HT(1A) and CB2 receptors. Neuropharmacology 71 (2013), 282–291.
56. [56] Martin-Moreno, A.M., Reigada, D., Ramirez, B.G., Mechoulam, R., Innamorato, N., Cuadrado, A., de Ceballos, M.L., Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease. Mol. Pharmacol. 79 (2011), 964–973.
57. [57] Valdeolivas, S., Satta, V., Pertwee, R.G., Fernandez-Ruiz, J., Sagredo, O., Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors. ACS Chem. Neurosci. 3 (2012), 400–406.
58. [58] Wolf, S.A., Bick-Sander, A., Fabel, K., Leal-Galicia, P., Tauber, S., Ramirez-Rodriguez, G., Muller, A., Melnik, A., Waltinger, T.P., Ullrich, O., Kempermann, G., Cannabinoid receptor CB1 mediates baseline and activity-induced survival of new neurons in adult hippocampal neurogenesis. Cell Commun. Signal., 8, 2010, 12.
59. [59] Bevilaqua, L., Ardenghi, P., Schroder, N., Bromberg, E., Schmitz, P.K., Schaeffer, E., Quevedo, J., Bianchin, M., Walz, R., Medina, J.H., Izquierdo, I., Drugs acting upon the cyclic adenosine monophosphate/protein kinase A signalling pathway modulate memory consolidation when given late after training into rat hippocampus but not amygdala. Behav. Pharmacol. 8 (1997), 331–338.
60. [60] Russo, E.B., Burnett, A., Hall, B., Parker, K.K., Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem. Res. 30 (2005), 1037–1043.
61. [61] Campos, A.C., Guimaraes, F.S., Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology 199 (2008), 223–230.
62. [62] Rock, E.M., Bolognini, D., Limebeer, C.L., Cascio, M.G., Anavi-Goffer, S., Fletcher, P.J., Mechoulam, R., Pertwee, R.G., Parker, L.A., Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus. Br. J. Pharmacol. 165 (2012), 2620–2634.
63. [63] Rock, E.M., Goodwin, J.M., Limebeer, C.L., Breuer, A., Pertwee, R.G., Mechoulam, R., Parker, L.A., Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews. Psychopharmacology 215 (2011), 505–512.
64. [64] Resstel, L.B., Tavares, R.F., Lisboa, S.F., Joca, S.R., Correa, F.M., Guimaraes, F.S., 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br. J. Pharmacol. 156 (2009), 181–188.
65. [65] Soares V de, P., Campos, A.C., Bortoli, V.C., Zangrossi, H. Jr., Guimaraes, F.S., Zuardi, A.W., Intra-dorsal periaqueductal gray administration of cannabidiol blocks panic-like response by activating 5-HT1A receptors. Behav. Brain Res. 213 (2010), 225–229.
66. [66] Campos, A.C., de Paula Soares, V., Carvalho, M.C., Ferreira, F.R., Vicente, M.A., Brandao, M.L., Zuardi, A.W., Zangrossi, H. Jr., Guimaraes, F.S., Involvement of serotonin-mediated neurotransmission in the dorsal periaqueductal gray matter on cannabidiol chronic effects in panic-like responses in rats. Psychopharmacology 226 (2013), 13–24.
67. [67] Gomes, F.V., Resstel, L.B., Guimaraes, F.S., The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors. Psychopharmacology 213 (2011), 465–473.
68. [68] Gomes, F.V., Reis, D.G., Alves, F.H., Correa, F.M., Guimaraes, F.S., Resstel, L.B., Cannabidiol injected into the bed nucleus of the stria terminalis reduces the expression of contextual fear conditioning via 5-HT1A receptors. J. Psychopharmacol. 26 (2012), 104–113.
69. [69] Fogaca, M.V., Reis, F.M., Campos, A.C., Guimaraes, F.S., Effects of intra-prelimbic prefrontal cortex injection of cannabidiol on anxiety-like behavior: involvement of 5HT1A receptors and previous stressful experience. Eur. Neuropsychopharmacol. 24 (2014), 410–419.
70. [70] Zanelati, T.V., Biojone, C., Moreira, F.A., Guimaraes, F.S., Joca, S.R., Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br. J. Pharmacol. 159 (2010), 122–128.
71. [71] Hayakawa, K., Mishima, K., Nozako, M., Ogata, A., Hazekawa, M., Liu, A.X., Fujioka, M., Abe, K., Hasebe, N., Egashira, N., Iwasaki, K., Fujiwara, M., Repeated treatment with cannabidiol but not delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance. Neuropharmacology 52 (2007), 1079–1087.
72. [72] Magen, I., Avraham, Y., Ackerman, Z., Vorobiev, L., Mechoulam, R., Berry, E.M., Cannabidiol ameliorates cognitive and motor impairments in bile-duct ligated mice via 5-HT1A receptor activation. Br. J. Pharmacol. 159 (2010), 950–957.
73. [73] Avraham, Y., Grigoriadis, N., Poutahidis, T., Vorobiev, L., Magen, I., Ilan, Y., Mechoulam, R., Berry, E., Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice. Br. J. Pharmacol. 162 (2011), 1650–1658.
74. [74] Pisoschiand, A.M., Pop, A., The role of antioxidants in the chemistry of oxidative stress: a review. Eur. J. Med. Chem. 97 (2015), 55–74.
75. [75] Niedzielska, E., Smaga, I., Gawlik, M., Moniczewski, A., Stankowicz, P., Pera, J., Filip, M., Oxidative stress in neurodegenerative diseases. Mol. Neurobiol., 2015, 10.1007/s12035-015-9337-5 (in press).
76. [76] Hampson, A.J., Grimaldi, M., Axelrod, J., Wink, D., Cannabidiol and (−)delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. U. S. A. 95 (1998), 8268–8273.
77. [77] El-Remessy, A.B., Khalil, I.E., Matragoon, S., Abou-Mohamed, G., Tsai, N.J., Roon, P., Caldwell, R.B., Caldwell, R.W., Green, K., Liou, G.I., Neuroprotective effect of (−)delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite. Am. J. Pathol. 163 (2003), 1997–2008.
78. [78] El-Remessy, A.B., Al-Shabrawey, M., Khalifa, Y., Tsai, N.T., Caldwell, R.B., Liou, G.I., Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am. J. Pathol. 168 (2006), 235–244.
79. [79] Iuvone, T., Esposito, G., Santamaria, R., Di Rosa, M., Izzo, A.A., Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J. Neurochem. 89 (2004), 134–141.
80. [80] Mecha, M., Torrao, A.S., Mestre, L., Carrillo-Salinas, F.J., Mechoulam, R., Guaza, C., Cannabidiol protects oligodendrocyte progenitor cells from inflammation-induced apoptosis by attenuating endoplasmic reticulum stress. Cell Death Dis., 3, 2012, e331.
81. [81] Massi, P., Vaccani, A., Bianchessi, S., Costa, B., Macchi, P., Parolaro, D., The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cell. Mol. Life Sci. 63 (2006), 2057–2066.
82. [82] Sarker, K.P., Obara, S., Nakata, M., Kitajima, I., Maruyama, I., Anandamide induces apoptosis of PC-12 cells: involvement of superoxide and caspase-3. FEBS Lett. 472 (2000), 39–44.
83. [83] Sagredo, O., Ramos, J.A., Decio, A., Mechoulam, R., Fernandez-Ruiz, J., Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors. Eur. J. Neurosci. 26 (2007), 843–851.
84. [84] O'Sullivan, S.E., Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br. J. Pharmacol. 152 (2007), 576–582.
85. [85] Kersten, S., Peroxisome proliferator activated receptors and lipoprotein metabolism. PPAR Res., 2008, 2008, 132960.
86. [86] Rodrigues, L.C., Gobira, P.H., de Oliveira, A.C., Pelicao, R., Teixeira, A.L., Moreira, F.A., Campos, A.C., Neuroinflammation as a possible link between cannabinoids and addiction. Acta Neuropsychiatr. 26 (2014), 334–346.
87. [87] Stahel, P.F., Smith, W.R., Bruchis, J., Rabb, C.H., Peroxisome proliferator-activated receptors: key regulators of neuroinflammation after traumatic brain injury. PPAR Res., 2008, 2008, 538141.
88. [88] Esposito, G., De Filippis, D., Maiuri, M.C., De Stefano, D., Carnuccio, R., Iuvone, T., Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement. Neurosci. Lett. 399 (2006), 91–95.
89. [89] Cho, H.Y., Gladwell, W., Wang, X., Chorley, B., Bell, D., Reddy, S.P., Kleeberger, S.R., Nrf2-regulated PPAR{gamma} expression is critical to protection against acute lung injury in mice. Am. J. Respir. Crit. Care Med. 182 (2010), 170–182.
90. [90] Juknat, A., Pietr, M., Kozela, E., Rimmerman, N., Levy, R., Coppola, G., Geschwind, D., Vogel, Z., Differential transcriptional profiles mediated by exposure to the cannabinoids cannabidiol and delta9-tetrahydrocannabinol in BV-2 microglial cells. Br. J. Pharmacol. 165 (2012), 2512–2528.
91. [91] Sonego, A.B., Sepulveda-Diaz, J.E., Michel, P.P., Del-Bel, E.A., Guimarães, F.S., Raisman-Vozari, R., Cannabidiol reduces LPS-induced activation and oxidative stress in primary microglial culture via PPARgamma receptor. Soc. Neurosci. Annu. Meet., 2015, 58 (Poster Abstract 4.10/R11, Book 2).
92. [92] Scuderi, C., Steardo, L., Esposito, G., Cannabidiol promotes amyloid precursor protein ubiquitination and reduction of beta amyloid expression in SHSY5YAPP+ cells through PPARgamma involvement. Phytother. Res. 28 (2014), 1007–1013.
93. [93] Barichello, T., Ceretta, R.A., Generoso, J.S., Moreira, A.P., Simoes, L.R., Comim, C.M., Quevedo, J., Vilela, M.C., Zuardi, A.W., Crippa, J.A., Teixeira, A.L., Cannabidiol reduces host immune response and prevents cognitive impairments in Wistar rats submitted to pneumococcal meningitis. Eur. J. Pharmacol. 697 (2012), 158–164.
94. [94] Valvassori, S.S., Elias, G., de Souza, B., Petronilho, F., Dal-Pizzol, F., Kapczinski, F., Trzesniak, C., Tumas, V., Dursun, S., Chagas, M.H., Hallak, J.E., Zuardi, A.W., Quevedo, J., Crippa, J.A., Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania. J. Psychopharmacol. 25 (2011), 274–280.
95. [95] Gomes, F.V., Llorente, R., Del Bel, E.A., Viveros, M.P., Lopez-Gallardo, M., Guimaraes, F.S., Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol. Schizophr. Res. 164 (2015), 155–163.
96. [96] Kozela, E., Juknat, A., Kaushansky, N., Ben-Nun, A., Coppola, G., Vogel, Z., Cannabidiol, a non-psychoactive cannabinoid, leads to EGR2-dependent anergy in activated encephalitogenic T cells. J. Neuroinflammation, 12(52), 2015.
97. [97] Esposito, G., Scuderi, C., Savani, C., Steardo, L. Jr., De Filippis, D., Cottone, P., Iuvone, T., Cuomo, V., Steardo, L., Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. Br. J. Pharmacol. 151 (2007), 1272–1279.
98. [98] Fogaça, M.V., Campos, A.C., Guimarães, F.S., Behavioural effects of cannabidiol in chronically stressed mice is mediated by neurogenesis and autophagy through CB1 receptor activation. Eur. Neuropsychopharmacol., 24(Suppl. 2), 2014, S606.
99. [99] Hosseinzadeh, M., Nikseresht, S., Khodagholi, F., Naderi, N., Maghsoudi, N., Cannabidiol post-treatment alleviates rat epileptic-related behaviors and activates hippocampal cell autophagy pathway along with antioxidant defense in chronic phase of pilocarpine-induced seizure. J. Mol. Neurosci., 2016, 10.1007/s12031-015-0703-6 (in press).
100. [100] Nabissi, M., Morelli, M.B., Amantini, C., Liberati, S., Santoni, M., Ricci-Vitiani, L., Pallini, R., Santoni, G., Cannabidiol stimulates Aml-1a-dependent glial differentiation and inhibits glioma stem-like cells proliferation by inducing autophagy in a TRPV2-dependent manner. Int. J. Cancer 137 (2015), 1855–1869.
101. [101] Carrier, E.J., Auchampach, J.A., Hillard, C.J., Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc. Natl. Acad. Sci. U. S. A. 103:20 (2006), 7895–7900.
102. [102] Mijangos-Moreno, S., Poot-Ake, A., Arankowsky-Sandoval, G., Murillo-Rodriguez, E., Intrahypothalamic injection of cannabidiol increases the extracellular levels of adenosine in nucleus accumbens in rats. Neurosci. Res. 84 (2014), 60–63.
103. [103] Liou, G.I., Auchampach, J.A., Hillard, C.J., Zhu, G., Yousufzai, B., Mian, S., Khan, S., Khalifa, Y., Mediation of cannabidiol anti-inflammation in the retina by equilibrative nucleoside transporter and A2A adenosine receptor. Invest. Ophthalmol. Vis. Sci. 49:12 (2008), 5526–5531.
104. [104] Nazario, L.R., Antonioli, R. Jr., Capiotti, K.M., Hallak, J.E., Zuardi, A.W., Crippa, J.A., Bonan, C.D., da Silva, R.S., Caffeine protects against memory loss induced by high and non-anxiolytic dose of cannabidiol in adult zebrafish (Danio rerio). Pharmacol. Biochem. Behav. 135 (2015), 210–216.
105. [105] Maione, S., Piscitelli, F., Gatta, L., Vita, D., De Petrocellis, L., Palazzo, E., de Novellis, V., Di Marzo, V., Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action. Br. J. Pharmacol. 162:3 (2011), 584–596.
106. [106] Hayakawa, K., Mishima, K., Abe, K., Hasebe, N., Takamatsu, F., Yasuda, H., Ikeda, T., Inui, K., Egashira, N., Iwasaki, K., Fujiwara, M., Cannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanism. Neuroreport 15 (2004), 2381–2385.
107. [107] Hayakawa, K., Mishima, K., Nozako, M., Hazekawa, M., Irie, K., Fujioka, M., Orito, K., Abe, K., Hasebe, N., Egashira, N., Iwasaki, K., Fujiwara, M., Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidase-inhibiting mechanism. J. Neurochem. 102 (2007), 1488–1496.
108. [108] Lastres-Becker, I., Molina-Holgado, F., Ramos, J.A., Mechoulam, R., Fernandez-Ruiz, J., Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol. Dis. 19 (2005), 96–107.
109. [109] Janefjord, E., Maag, J.L., Harvey, B.S., Smid, S.D., Cannabinoid effects on beta amyloid fibril and aggregate formation, neuronal and microglial-activated neurotoxicity in vitro. Cell. Mol. Neurobiol. 34 (2014), 31–42.
110. [110] Harvey, B.S., Ohlsson, K.S., Maag, J.L., Musgrave, I.F., Smid, S.D., Contrasting protective effects of cannabinoids against oxidative stress and amyloid-beta evoked neurotoxicity in vitro. Neurotoxicology 33 (2012), 138–146.
111. [111] Pryce, G., Riddall, D.R., Selwood, D.L., Giovannoni, G., Baker, D., Neuroprotection in experimental autoimmune encephalomyelitis and progressive multiple sclerosis by cannabis-based cannabinoids. J. Neuroimmune Pharmacol. 10 (2015), 281–292.
112. [112] Ward, S.J., McAllister, S.D., Kawamura, R., Murase, R., Neelakantan, H., Walker, E.A., Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy. Br. J. Pharmacol. 171 (2014), 636–645.
113. [113] Ibeas Bih, C., Chen, T., Nunn, A.V., Bazelot, M., Dallas, M., Whalley, B.J., Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics 12 (2015), 699–730.
114. [114] Zuardi, A.W., Finkelfarb, E., Bueno, O.F., Musty, R.E., Karniol, I.G., Characteristics of the stimulus produced by the mixture of cannabidiol with delta 9-tetrahydrocannabinol. Arch. Int. Pharmacodyn. Ther. 249 (1981), 137–146.
115. [115] Hine, B., Torrelio, M., Gershon, S., Differential effect of cannabinol and cannabidiol on THC-induced responses during abstinence in morphine-dependent rats. Res. Commun. Chem. Pathol. Pharmacol. 12:1 (1975), 185–188.
116. [116] Izquierdo, I., Orsingher, O.A., Berardi, A.C., Effect of cannabidiol and of other cannabis sativa compounds on hippocampal seizure discharges. Psychopharmacologia 28:1 (1973), 95–102.
117. [117] Consroe, P., Laguna, J., Allender, J., Snider, S., Stern, L., Sandyk, R., Kennedy, K., Schram, K., Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol. Biochem. Behav. 40:3 (1991), 701–708.
118. [118] Moreno-Martet, M., Espejo-Porras, F., Fernández-Ruiz, J., de Lago, E., Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of a Sativex(®) -like combination of phytocannabinoids: interest for future therapies in amyotrophic lateral sclerosis. CNS Neurosci. Ther. 20:9 (2014), 809–815.
119. [119] Wade, D.T., Robson, P., House, H., Makela, P., Aram, J., A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin. Rehabil. 17:1 (2003), 21–29.